CAJ | 학술논문

目的：探讨对于慢性阻塞性肺疾病（ chronic obstructive pulmonary disease ，COPD）稳定期患者给予口服瑞舒伐他汀16周后血清白介素8（IL－8）水平、肺功能及生活质量的影响，并观察使用他汀类药物干预后对患者远期（1年）COPD急性加重（acute exacerbation of COPD，AECOPD）次数的影响。方法 COPD门诊及出院患者随机分组，分为治疗组40例，对照组42例。治疗组40例在常规治疗的基础上口服瑞舒伐他汀20 mg，1／d，治疗后16周后复诊观察患者血清IL－8、肺功能（ FEV1及FEV1／FVC）、圣乔治呼吸问卷评分（ St George's respiratory questionnaire scores ，SGRQ）评估生活质量。随访1年，记录1年内患者出现AECOPD的次数及住院次数。结果治疗组和对照组比较，治疗组在第16周时血清IL－8水平较对照组下降（ P＜0．05），肺功能FEV1及FEV1／FVC较对照组改善（P＜0．05），SGRQ评分较对照组增加，但差异无统计学意义（P＞0．05）。远期观察治疗组患者急性加重次数和住院次数较对照组减少（ P＜0．05）。结论瑞舒伐他汀有助于改善COPD患者的肺功能及生活质量，并有减少远期急性加重的临床效应。
목적：탐토대우만성조새성폐질병（ chronic obstructive pulmonary disease ，COPD）은정기환자급여구복서서벌타정16주후혈청백개소8（IL－8）수평、폐공능급생활질량적영향，병관찰사용타정류약물간예후대환자원기（1년）COPD급성가중（acute exacerbation of COPD，AECOPD）차수적영향。방법 COPD문진급출원환자수궤분조，분위치료조40례，대조조42례。치료조40례재상규치료적기출상구복서서벌타정20 mg，1／d，치료후16주후복진관찰환자혈청IL－8、폐공능（ FEV1급FEV1／FVC）、골교치호흡문권평분（ St George's respiratory questionnaire scores ，SGRQ）평고생활질량。수방1년，기록1년내환자출현AECOPD적차수급주원차수。결과치료조화대조조비교，치료조재제16주시혈청IL－8수평교대조조하강（ P＜0．05），폐공능FEV1급FEV1／FVC교대조조개선（P＜0．05），SGRQ평분교대조조증가，단차이무통계학의의（P＞0．05）。원기관찰치료조환자급성가중차수화주원차수교대조조감소（ P＜0．05）。결론서서벌타정유조우개선COPD환자적폐공능급생활질량，병유감소원기급성가중적림상효응。
Objective To investigate the effect of oral rosuvastatin treatment of stable COPD patients on the blood IL -8, lung function and quality of life, after short-term (16 weeks) and long-term observation of the times of acute exacerbation of COPD (AECO-PD) after the intervention (1 year) .Methods The outpatients and discharged patients with COPD were randomly divided into treat -ment group 40 cases and control group 42 groups , the treatment group were treated with rosuvastatin 20 mg QN on the basis of routine treatment.16 weeks after operation we observed all patients 'serum IL-8, lung function (FEV1 and FEV1/FVC), and quality of life (St George's respiratory questionnaire scores ).We recorded the frequency of AECOPD and hospitalization followed up for 1 year.Re-sults Compared with the treatment group and control group at sixteenth weeks , the blood IL-8 level in the patients in the treatment group decreased (P<0.05), pulmonary function of FEV1 and FEV1/FVC improved (P<0.05), SGQR score increased, but there was no statistical difference (P>0.05).The data of long-term observation shows the patients in the treatment group has less times of acute exacerbation and hospitalization times than the control group (P<0.05).Conclusion The rosuvastatin improves lung function and quality of life in patients with COPD , and has long-term clinical effect in reducing acute exacerbation .